Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease

摘要: Abstract Introduction Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q 10 (CoQ ) is the electron acceptor complexes and II, a potent antioxidant. A recent trial oxidized form CoQ for PD failed to show benefits; however, reduced (ubiquinol-10) has shown better neuroprotective effects animal models. Methods Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted assess efficacy ubiquinol-10 Japanese PD. Participants divided into two groups: experiencing wearing off (Group A), early PD, without levodopa (with or dopamine agonist) B). took 300 mg placebo per day 48 weeks A) 96 Results In Group A, total Unified Disease Rating Scale (UPDRS) scores decreased group (n = 14; mean ± SD [−4.2 ± 8.2]), indicating improvement symptoms. There was statistically significant difference ( p Conclusions This first report showing that may significantly improve off, as judged by UPDRS scores, safe well tolerated.